Sun Pharma Advanced Research Co (NSE:SPARC) Total Debt per Share: ₹0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SPARC Sun Pharma Advanced Research Co Ltd NSE:SPARC
48 GF Score
Price ₹204.28
GF Value ₹4,436.18
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Sun Pharma Advanced Research Co Total Debt per Share?

Sun Pharma Advanced Research Co NSE:SPARC +1.02% 48 Total Debt per Share is ₹0.00 as of Jun. 2026. GuruFocus rates NSE:SPARC with a GF Score™ of 48/100 and a GF Value™ of ₹4,436.18 (Possible Value Trap). The stock has 4 warning signs investors should review.

₹0.00 (As of Jun. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Sun Pharma Advanced Research Co's Total Debt Per Share for the quarter that ended in Jun. 2026 was ₹0.00.

Sun Pharma Advanced Research Co Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Sun Pharma Advanced Research Co's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sun Pharma Advanced Research Co Total Debt per Share Chart

Sun Pharma Advanced Research Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.91 0.48 1.78 8.17 17.19

Sun Pharma Advanced Research Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 12.84 0.00 17.19 0.00
NSE:SPARC
48GF Score
Sun Pharma Advanced Research Co Ltd NSE:SPARC
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sun Pharma Advanced Research Co Total Debt per Share Calculation

Sun Pharma Advanced Research Co's Total Debt Per Share for the fiscal year that ended in Mar. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(17+5,561)/325
=17.19

Sun Pharma Advanced Research Co's Total Debt Per Share for the quarter that ended in Jun. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0+0)/325
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of ₹0.00 mean?
Sun Pharma Advanced Research Co (NSE:SPARC) has a Total Debt per Share of ₹0.00 as of Jun. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Sun Pharma Advanced Research Co and its competitors.
Is Sun Pharma Advanced Research Co's Total Debt per Share too high?
Sun Pharma Advanced Research Co's current Total Debt per Share is ₹0.00. Overall, Sun Pharma Advanced Research Co has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sun Pharma Advanced Research Co's Total Debt per Share compare to ZTS?
Sun Pharma Advanced Research Co's Total Debt per Share of ₹0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Drug Manufacturers company?
A good Total Debt per Share depends on the Drug Manufacturers industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Sun Pharma Advanced Research Co and its competitors. Sun Pharma Advanced Research Co's current Total Debt per Share is ₹0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sun Pharma Advanced Research Co stock overvalued right now?
Based on GuruFocus' analysis, Sun Pharma Advanced Research Co (NSE:SPARC) is currently considered Possible Value Trap. The stock's GF Value™ is ₹4,436.18, compared to a current price of ₹204.28 — trading 95.4% below its estimated fair value. The current Total Debt per Share is ₹0.00. Sun Pharma Advanced Research Co's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Sun Pharma Advanced Research Co (NSE:SPARC), the current Total Debt per Share is ₹0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sun Pharma Advanced Research Co (NSE:SPARC) Overvalued in 2026?

Based on GuruFocus' analysis, Sun Pharma Advanced Research Co stock appears to be undervalued. The current stock price of ₹204.28 is trading 95.4% below its estimated GF Value™ of ₹4,436.18. GuruFocus considers Sun Pharma Advanced Research Co to be Possible Value Trap.

Key valuation signals for NSE:SPARC:

  • Total Debt per Share: ₹0.00
  • GF Value™: ₹4,436.18 vs. price of ₹204.28 (95.4% below fair value)
  • GF Score™: 48/100 with 4 warning signs

No single metric tells the full story. See the NSE:SPARC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sun Pharma Advanced Research Co Business Description

Other Exchanges 532872:India
Address Off Mahakali Caves Road, 17-B, Mahal Industrial Estate, Andheri (East), Mumbai, MH, IND, 400093
Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. It derives maximum revenue from India and also has its presence in other countries.
48GF Score

Get the complete analysis for NSE:SPARC

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹204.28
Price
₹4,436.18
GF Value